Bearpac Medical, LLC is pleased to announce that the FDA has granted 510(k) clearance for the Passio Pump Drainage System for the additional indication of peritoneal to provide therapy for malignant ascites in addition to recurrent pleural effusions.
Bearpac Medical Announces Peritoneal Indication for the Passio Pump Drainage System Read More »
Coya Therapeutics, Inc. announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock.
Coya Therapeutics Announces $26.5 Million Private Placement Read More »
Alentis Therapeutics today announced that Rizwan Velji has been appointed Chief Business Officer (CBO).
Delix Therapeutics, a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001.
Geron Corporation today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from its Phase 4, open-label clinical trial of VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in the head and neck region in adults (N=31).
Kaneka Corporation has acquired all shares of Japan Medical Device Technology Co., Ltd., a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.
Camena Bioscience Appoints Dr Nicola Thompson as Chair of the Board Read More »
EVONETIX LTD, the company developing semiconductor scale technology to improve access to gene synthesis, announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc., a global semiconductor leader.
Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.
